Arcus Biosciences, a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, obtained a $250 million term loan facility from Hercules Capital. The additional...
Read Story
August 28, 2024, 07:50 AM
|
B. Riley Securities led a $46.9 million financing for Radiopharm Theranostics Limited ("RAD"), an ASX listed clinical stage biotechnology company developing targeted radiopharmaceutical therapies and diagnostics for multiple types of cancer. The...
Read Story
|
SSG Capital Advisors served as the investment banker to the Chapter 7 Trustee of ContraFect Corporation, in the sale of substantially all intellectual property assets to Aurobac Therapeutics SAS. The transaction closed in March 2024 through a Section...
Read Story
|
Armata Pharmaceuticals, a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, entered into a secured credit agreement with Innoviva Strategic...
Read Story
|
Trinity Capital announced the commitment of $25 million in growth capital to Neuros Medical, Inc., a bioelectric technology company focused on alleviating chronic post-amputation pain and restoring quality of life. The growth capital will enable...
Read Story
November 01, 2023, 07:55 AM
|
Horizon Technology Finance provided a $15 million venture loan facility to Tallac Therapeutics, Inc., of which $5 million has been initially funded.Tallac is developing multiple novel immunotherapies to fight cancer. Tallac's innovative Toll-like...
Read Story
August 07, 2023, 05:00 AM
|
Harmony Biosciences Holdings, a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, entered into a new $185 million senior secured term loan facility with a bank...
Read Story
|
COMPASS Pathways plc, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, entered into a term loan agreement with Hercules Capital for up to $50 million. Kabir Nath, COMPASS Pathways Chief...
Read Story
|
Aspen Neuroscience, a private biotechnology company developing autologous cell therapies including the first iPSC-derived autologous neuron replacement treatment for Parkinson's disease (PD), signed a $40 million credit facility with Silicon Valley...
Read Story
December 22, 2022, 07:34 AM
|
Evelo Biosciences entered into a senior secured loan agreement with Horizon Technology Finance. The $45 million term loan, which provides for three years of interest-only payments followed by a two-year amortization period, replaces the Company’s...
Read Story
December 19, 2022, 07:43 AM
|
CIT, a division of First Citizens Bank, announced that its Healthcare Finance business served as lead arranger of $135.6 million in financing for Superior Biologics Inc.Headquartered in Sharon Hill, Pennsylvania, Superior Biologics is a leading...
Read Story
December 02, 2022, 07:00 AM
|
PDS Biotechnology entered into a debt financing agreement led by Horizon Technology Finance Corporation to provide up to a $35.0 million term loan.As part of the financing, PDS Biotech received an initial tranche of $25 million at the close. The...
Read Story
August 25, 2022, 07:45 AM
|
ADC Therapeutics SA completed a series of strategic transactions in which it:
Entered into a new $175 million senior secured term loan with certain funds of Owl Rock, a division of Blue Owl Capital, Inc. ("Owl Rock"), and funds managed by Oaktree...
Read Story
August 16, 2022, 07:55 AM
|
atai Life Sciences N.V., a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that the company has entered into a term loan facility for up to $175 million with Hercules Capital. Under the...
Read Story
August 15, 2022, 07:52 AM
|
SSG Advisors acted as the investment banker to Retrotope, Inc. in the sale of substantially all of its assets to RTMFP Enterprises Inc. (“RTMFP”). The sale was effectuated through a Section 363 sale under a confirmed Chapter 11 Sub-Chapter V Plan of...
Read Story
|
Theratechnologies, a biopharmaceutical company focused on the development and commercialization of innovative therapies, received funding of $40 million under the terms of its credit agreement with affiliated funds of Marathon Asset Management. This...
Read Story
|
Gritstone bio, a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, entered into an $80 million credit facility with Hercules Capital and Silicon Valley Bank."This non-dilutive facility enhances our financial...
Read Story
|
Theratechnologies, a biopharmaceutical company focused on the development and commercialization of innovative therapies, received a binding commitment with respect to a non-dilutive term loan with an affiliate of Marathon Asset Management for up to...
Read Story
|
Viridian Therapeutics, a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, entered into a debt financing agreement with Hercules Capital for up to $75 million. Under the...
Read Story
|
Mustang Bio, a clinical-stage biopharmaceutical company announced completion of a $75 million long-term debt facility with Runway Growth Capital, a leading provider of growth loans to both venture and non-venture backed companies seeking an...
Read Story
|
Oxford Finance closed a $50 million senior secured term loan with OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders.Proceeds from the transaction will be used for...
Read Story
February 16, 2022, 08:00 AM
|
Liquidia Corporation closed a debt facility on January 7, 2022, with Silicon Valley Bank (SVB) which provides Liquidia with up to $40.0 million in term loans of which the first $20.0 million was funded at closing. Liquidia initially entered a debt...
Read Story
January 10, 2022, 08:00 AM
|
Coherus BioSciences entered into a loan agreement with investment funds managed by Pharmakon Advisors, LP.“As Coherus enters a period of projected significant topline growth and diversification of our commercial product portfolio, we are pleased to...
Read Story
January 10, 2022, 07:07 AM
|
TG Therapeutics announced that its existing term loan facility agreement with Hercules Capital has been amended to increase the size of the facility to $200 million, with $70 million funded at closing. Michael S. Weiss, Chairman and Chief Executive...
Read Story
January 04, 2022, 07:40 AM
|
Oxford Finance closed a $50 million senior secured term loan with Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders.Proceeds from the...
Read Story
November 11, 2021, 07:59 AM
|
Oxford Finance closed a $20 million senior secured term loan with PlateletBio, a preclinical-stage biotechnology company pioneering an entirely new platform of allogeneic cell therapies based on platelet biology.The funds will be used for general...
Read Story
November 10, 2021, 07:43 AM
|
Gemini Bioproducts, LLC ("GeminiBio"), a leading manufacturer of cell culture products and custom cGMP bioprocess liquids, secured financing from BroadOak Capital Partners, LLC ("BroadOak"), a boutique direct investment and advisory firm focused on...
Read Story
November 08, 2021, 07:54 AM
|
Amerisource Business Capital announced the closing and funding of a $1,000,000 senior credit facility for a Texas-based Bioscience firm. The proceeds were used to support growth and working capital needs. Daniel Martinez, Regional Market Manager for...
Read Story
November 03, 2021, 07:30 AM
|
Axsome Therapeutics announced that its existing term loan facility agreement with Hercules Capital has been amended to increase the size of the facility to $300 million, and the amount immediately available upon U.S. Food and Drug Administration...
Read Story
October 19, 2021, 07:49 AM
|
Interpace Biosciences, along with its subsidiaries, entered into a new $7.5 million revolving credit facility with Comerica Bank. The facility matures on September 30, 2023 and allows for advances based on 80% of eligible accounts receivable plus an...
Read Story
October 18, 2021, 07:09 AM
|
Aptinyx, a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, entered into a $50 million loan facility and security agreement with K2 HealthVentures (K2HV). The funds...
Read Story
September 16, 2021, 07:42 AM
|
Kane Biotech entered into an amended and restated credit agreement with Pivot Financial dated August 31, 2021.The Amended Credit Facility amends and restates the existing credit agreement with Pivot dated November 5, 2020, increasing the credit...
Read Story
September 03, 2021, 07:11 AM
|
Runway Growth Capital closed a senior secured term loan of $35 million to SetPoint Medical, a Valencia, California based, privately-held clinical-stage bioelectronic medicine company developing therapies for chronic autoimmune diseases.In the past...
Read Story
|
INmune Bio entered into a new $15 million credit facility with Silicon Valley Bank (SVB) and an affiliate of SVB Financial Group. INmune intends to use the proceeds from the facility to partially fund the buyout of an option held by Xencor, Inc....
Read Story
|
Cerecor Inc. entered into a debt financing agreement led by Horizon Technology Finance Corporation to provide up to $35.0 million in term loans.“We are pleased to partner with Horizon, a leading specialty finance company that has an extensive history...
Read Story
|
HiberCell completed a Series B financing round for gross proceeds of $67.4 million. Concurrent to this financing, HiberCell closed on a $30 million debt facility with Hercules Capital.The Series B round included new investors Huizenga Capital...
Read Story
|
SCYNEXIS secured a $60 million term loan facility with Hercules Capital and Silicon Valley Bank (SVB). The capital strengthens SCYNEXIS’ balance sheet ahead of the anticipated commercial launch of Brexafemme, the expected trade name for ibrexafungerp...
Read Story
|
Abacus Finance Group served as Administrative Agent and Sole Lead Arranger for senior secured credit facilities to support the refinance of LifeSpan Biosciences, Inc. (LSBio) by Thompson Street Capital Partners. Abacus also made an equity...
Read Story
|
According to an 8K filed with the SEC, on March 8, 2021, Illumina, Inc. entered into a credit agreement by and among the Company, as the borrower, the lenders from time to time party thereto and Bank of America, as administrative agent.The Credit...
Read Story
|
Radius Health announced that the Company has entered into amended and restated credit facilities in the aggregate principal amount of $175 million, consisting of a $150 million term loan, which includes a cashless conversion of $25 million in...
Read Story
|
Harvard Bioscience, Inc. announced the refinancing of its debt with the closing of a new $65 million credit facility. Proceeds from the new facility will be used to retire existing debt and pay related fees and expenses. The Refinancing significantly...
Read Story
December 23, 2020, 08:35 AM
|
Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it has entered into a debt financing facility for up to $30 million (“debt facility”) with Silicon Valley Bank (SVB). The non-dilutive...
Read Story
November 23, 2020, 08:15 AM
|
Fortress Biotech, an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, announced that it has entered into a $60...
Read Story
August 28, 2020, 08:05 AM
|
InformedDNA, the nation’s largest provider of genetics services, announced that it has entered into definitive agreements with TT Capital Partners (TTCP), NovaQuest Capital Management (NovaQuest) and Frist Cressey Ventures to make meaningful growth...
Read Story
December 24, 2019, 08:50 AM
|
Capital One announced today that it acted as a joint lead arranger for a senior secured credit facility for STEMCELL Technologies, a Canada-based biotechnology and life science company. The financing consists of a revolving line of credit and a...
Read Story
August 20, 2019, 08:50 AM
|
Meridian Bioscience has entered into a $125 million revolving credit facility credit agreement, it said in a regulatory filing.The credit agreement, which took effect on May 24, replaces the Cincinnati-based company's loan and security agreement...
Read Story
|
Fueled by a desire for innovation and new medical breakthroughs, the biotech industry continues to enjoy substantial growth due to increased investment in research and development (R&D), according to the sixth annual study from BDO USA, LLP.The 2017...
Read Story
|
Oxford Finance LLC, a specialty finance firm that provides senior debt to life sciences and healthcare services companies, and Silicon Valley Bank announced the closing of a $20 million credit facility with Castle Biosciences, Inc., a privately held...
Read Story
|
T2 Biosystems, Inc., a company developing innovative diagnostic products that improve patient health and deliver a strong economic return to healthcare institutions, today announced that it has entered into a $50 million debt facility agreement with...
Read Story
January 06, 2017, 07:30 AM
|
Ocata Therapeutics, Inc. has entered into a secured term loan facility of up to $10 million with Silicon Valley Bank. Ocata received initial funding of $6 million and has a conditional option to receive an additional $4 million upon the successful...
Read Story
August 20, 2015, 07:15 AM
|
Oxford Finance and Silicon Valley Bank announced the closing of a credit facility, including a $10 million senior secured term loan and a $7 million line of credit, with Labcyte Inc. Labcyte is a global biotechnology tools company that is...
Read Story
|